Starlake Bioscience Co Inc Zhaoqing Guangdong

SHG:600866 China Biotechnology
Market Cap
$1.82 Billion
CN¥13.37 Billion CNY
Market Cap Rank
#7351 Global
#1243 in China
Share Price
CN¥8.05
Change (1 day)
+0.25%
52-Week Range
CN¥6.03 - CN¥8.39
All Time High
CN¥9.46
Categories
Companies in China Biotechnology
About

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more

Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) - Net Assets

Latest net assets as of September 2025: CN¥8.50 Billion CNY

Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has net assets worth CN¥8.50 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.27 Billion) and total liabilities (CN¥8.77 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.50 Billion
% of Total Assets 49.21%
Annual Growth Rate 13.74%
5-Year Change 381.21%
10-Year Change 666.27%
Growth Volatility 55.78

Starlake Bioscience Co Inc Zhaoqing Guangdong - Net Assets Trend (1994–2024)

This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2024)

The table below shows the annual net assets of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2024.

Year Net Assets Change
2024-12-31 CN¥8.03 Billion +4.86%
2023-12-31 CN¥7.66 Billion +10.54%
2022-12-31 CN¥6.93 Billion +290.24%
2021-12-31 CN¥1.78 Billion +6.39%
2020-12-31 CN¥1.67 Billion +9.78%
2019-12-31 CN¥1.52 Billion +58.96%
2018-12-31 CN¥956.42 Million +4.63%
2017-12-31 CN¥914.14 Million -14.76%
2016-12-31 CN¥1.07 Billion +2.32%
2015-12-31 CN¥1.05 Billion -28.61%
2014-12-31 CN¥1.47 Billion +0.19%
2013-12-31 CN¥1.47 Billion -10.35%
2012-12-31 CN¥1.63 Billion -9.30%
2011-12-31 CN¥1.80 Billion +12.00%
2010-12-31 CN¥1.61 Billion +57.72%
2009-12-31 CN¥1.02 Billion +31.40%
2008-12-31 CN¥776.46 Million +4.64%
2007-12-31 CN¥742.02 Million -16.83%
2006-12-31 CN¥892.18 Million +1.98%
2005-12-31 CN¥874.86 Million -2.07%
2004-12-31 CN¥893.38 Million -1.24%
2003-12-31 CN¥904.58 Million +8.34%
2002-12-31 CN¥834.94 Million +10.50%
2001-12-31 CN¥755.58 Million +0.56%
2000-12-31 CN¥751.40 Million +6.81%
1999-12-31 CN¥703.50 Million +56.94%
1998-12-31 CN¥448.25 Million +11.20%
1997-12-31 CN¥403.09 Million +89.72%
1996-12-31 CN¥212.46 Million +23.66%
1995-12-31 CN¥171.81 Million +1.92%
1994-12-31 CN¥168.57 Million --

Equity Component Analysis

This analysis shows how different components contribute to Starlake Bioscience Co Inc Zhaoqing Guangdong's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 5094.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.31 Billion 16.62%
Common Stock CN¥1.66 Billion 21.09%
Other Comprehensive Income CN¥266.48 Million 3.38%
Other Components CN¥4.64 Billion 58.90%
Total Equity CN¥7.88 Billion 100.00%

Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Market Cap

The table below lists competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong ranked by their market capitalization.

Company Market Cap
Clarkson PLC
PINK:CKNHF
 		$990.23 Million
Alliance Financial Group Bhd
KLSE:2488
 		$990.26 Million
The First Bancshares, Inc.
NASDAQ:FBMS
 		$990.47 Million
Khang Dien House Trading and Investment JSC
VN:KDH
 		$991.00 Million
Schaeffler AG
PINK:SFFLY
 		$989.80 Million
Digi Communications NV
RO:DIGI
 		$989.72 Million
L&T Technology Services Limited
NSE:LTTS
 		$989.37 Million
Dno ASA
PINK:DTNOF
 		$989.01 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Starlake Bioscience Co Inc Zhaoqing Guangdong's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,561,695,028 to 7,876,583,459, a change of 314,888,431 (4.2%).
  • Net income of 943,152,843 contributed positively to equity growth.
  • Dividend payments of 746,188,748 reduced retained earnings.
  • Other comprehensive income increased equity by 266,483,418.
  • Other factors decreased equity by 148,559,082.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥943.15 Million +11.97%
Dividends Paid CN¥746.19 Million -9.47%
Other Comprehensive Income CN¥266.48 Million +3.38%
Other Changes CN¥-148.56 Million -1.89%
Total Change CN¥- 4.16%

Book Value vs Market Value Analysis

This analysis compares Starlake Bioscience Co Inc Zhaoqing Guangdong's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.70x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 24.89x to 1.70x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.32 CN¥8.05 x
1995-12-31 CN¥0.33 CN¥8.05 x
1996-12-31 CN¥0.41 CN¥8.05 x
1997-12-31 CN¥0.77 CN¥8.05 x
1998-12-31 CN¥0.86 CN¥8.05 x
1999-12-31 CN¥1.35 CN¥8.05 x
2000-12-31 CN¥1.44 CN¥8.05 x
2001-12-31 CN¥1.44 CN¥8.05 x
2002-12-31 CN¥1.59 CN¥8.05 x
2003-12-31 CN¥1.73 CN¥8.05 x
2004-12-31 CN¥1.71 CN¥8.05 x
2005-12-31 CN¥1.68 CN¥8.05 x
2006-12-31 CN¥1.71 CN¥8.05 x
2007-12-31 CN¥1.42 CN¥8.05 x
2008-12-31 CN¥1.49 CN¥8.05 x
2009-12-31 CN¥1.92 CN¥8.05 x
2010-12-31 CN¥2.95 CN¥8.05 x
2011-12-31 CN¥3.16 CN¥8.05 x
2012-12-31 CN¥2.72 CN¥8.05 x
2013-12-31 CN¥2.91 CN¥8.05 x
2014-12-31 CN¥2.66 CN¥8.05 x
2015-12-31 CN¥1.61 CN¥8.05 x
2016-12-31 CN¥1.76 CN¥8.05 x
2017-12-31 CN¥1.44 CN¥8.05 x
2018-12-31 CN¥1.58 CN¥8.05 x
2019-12-31 CN¥2.06 CN¥8.05 x
2020-12-31 CN¥2.26 CN¥8.05 x
2021-12-31 CN¥2.40 CN¥8.05 x
2022-12-31 CN¥5.79 CN¥8.05 x
2023-12-31 CN¥4.55 CN¥8.05 x
2024-12-31 CN¥4.74 CN¥8.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Starlake Bioscience Co Inc Zhaoqing Guangdong utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.97%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.44%
  • • Asset Turnover: 1.19x
  • • Equity Multiplier: 1.85x
  • Recent ROE (11.97%) is above the historical average (4.08%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 14.95% 9.35% 0.84x 1.91x CN¥8.34 Million
1995 11.80% 5.85% 0.96x 2.09x CN¥3.09 Million
1996 14.52% 8.50% 0.94x 1.81x CN¥9.59 Million
1997 14.91% 21.27% 0.55x 1.27x CN¥19.80 Million
1998 13.75% 20.41% 0.49x 1.37x CN¥16.83 Million
1999 10.04% 24.34% 0.34x 1.20x CN¥253.85K
2000 11.44% 24.65% 0.32x 1.44x CN¥10.85 Million
2001 9.01% 15.40% 0.44x 1.33x CN¥-7.48 Million
2002 9.47% 15.98% 0.48x 1.23x CN¥-4.44 Million
2003 7.92% 13.09% 0.47x 1.30x CN¥-18.79 Million
2004 4.37% 8.53% 0.35x 1.46x CN¥-50.25 Million
2005 1.48% 2.17% 0.44x 1.56x CN¥-74.49 Million
2006 2.15% 2.50% 0.55x 1.58x CN¥-70.02 Million
2007 -18.68% -18.02% 0.57x 1.82x CN¥-212.75 Million
2008 3.74% 2.95% 0.72x 1.75x CN¥-48.49 Million
2009 22.47% 16.44% 0.91x 1.50x CN¥124.58 Million
2010 18.55% 20.70% 0.60x 1.50x CN¥131.37 Million
2011 5.12% 8.25% 0.31x 2.00x CN¥-83.60 Million
2012 -13.54% -18.59% 0.33x 2.22x CN¥-352.68 Million
2013 1.37% 2.24% 0.35x 1.77x CN¥-127.04 Million
2014 -24.45% -41.40% 0.39x 1.53x CN¥-508.35 Million
2015 -40.30% -57.88% 0.40x 1.76x CN¥-527.16 Million
2016 2.27% 3.58% 0.40x 1.59x CN¥-82.93 Million
2017 -17.31% -23.04% 0.47x 1.58x CN¥-249.69 Million
2018 4.42% 4.92% 0.59x 1.51x CN¥-53.36 Million
2019 9.84% 14.25% 0.50x 1.39x CN¥-2.48 Million
2020 8.91% 13.32% 0.46x 1.45x CN¥-18.19 Million
2021 8.57% 3.74% 1.65x 1.39x CN¥-25.42 Million
2022 8.84% 3.48% 1.09x 2.33x CN¥-79.76 Million
2023 8.97% 3.90% 1.21x 1.90x CN¥-78.22 Million
2024 11.97% 5.44% 1.19x 1.85x CN¥155.49 Million

Industry Comparison

This section compares Starlake Bioscience Co Inc Zhaoqing Guangdong's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,722,009,584
  • Average return on equity (ROE) among peers: 7.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) CN¥8.50 Billion 14.95% 1.03x $990.13 Million
Shenzhen CAU Technology Co Ltd (000004) $183.33 Million -11.06% 0.92x $80.66 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $966.91 Million 19.23% 0.71x $1.03 Billion
Nanhua Bio Medicine Co Ltd (000504) $387.30 Million 7.50% 0.60x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $248.75 Million
Chengzhi Shareholding Co Ltd (000990) $1.65 Billion 1.65% 0.84x $860.44 Million
Hualan Biological EngineeringInc (002007) $4.84 Billion 16.95% 0.08x $2.01 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.20 Billion 4.62% 0.66x $793.09 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $763.33 Million 17.77% 0.08x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $1.81 Billion 11.12% 0.67x $414.37 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $3.77 Billion 15.42% 0.67x $347.52 Million